<DOC>
	<DOCNO>NCT02670577</DOCNO>
	<brief_summary>The scope study measure impact MammaPrint treatment Hormone Receptor ( HR ) -positive HER2-negative breast cancer patient . In addition , impact MammaPrint treatment patient T1a/T1b pN0/pN1 ( 1 node ) , Triple Negative HER2-positive tumor assess .</brief_summary>
	<brief_title>Measuring Impact MammaPrint Adjuvant Neoadjuvant Treatment Breast Cancer Patients : A Prospective Registry</brief_title>
	<detailed_description>Eligible patient tumor sample analyze MammaPrint , BluePrint TargetPrint . Patients start treatment MammaPrint BluePrint result receive take consideration treatment plan . The clinical data enter online . There 2 Case Report Forms ( CRFs ) . Baseline clinical data physician chemotherapy intention know MammaPrint BluePrint result enter CRF 1 . After completion CRF1 , MammaPrint BluePrint result release . CRF2 complete final treatment decision make . This CRF capture physician chemotherapy intention MammaPrint BluePrint result impact result . A sample size 331 patient require detect 25 % overall treatment change ( 5 % significance 95 % power ) stage I II HR-positive , HER2-negative patient receive adjuvant therapy . In addition least 50 T1a/bN0/1 ( 1 node ) Triple Negative , least 50 T1a/bN0/1 ( 1 node ) HER2-positive breast cancer patient , least 50 patient receive neoadjuvant therapy enrol .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Eligible receive chemotherapy endocrine therapy define good Karnofsky index ( ≥80 ) hematologic , cardiologic hepatic contraindication , impede comorbidity Informed consent form sign day enrollment ≥ 18 year age time consent Per study arm Histologically proven invasive stage I II breast cancer Hormone Receptor positive ( ER+ PR , ER PR+ ER+ PR+ ) accord local standard &amp; HER2 negative : IHC 01+ , FISH ISH nonamplified ( locally assess ) IMPACt study ; version 1 2015 September 1 Page 10 Axillary lymph node status : 03 involve ( macro metastasis i.e . &gt; 2mm OR micro metastasis i.e . &gt; 0.22mm ) OR Histologically proven invasive T1a T1b breast cancer &amp; Hormone receptor negative ( ER PR ) accord local standard &amp; HER2 negative : IHC 01+ , FISH ISH nonamplified ( locally assess ) &amp; Axillary lymph node status : 01 involve ( macro metastasis i.e . &gt; 2mm OR micro metastasis i.e . &gt; 0.22mm ) OR Histologically proven invasive T1a T1b breast cancer &amp; Hormone receptor negative positive ( ERPR , ER+PR , ERPR+ , ER+PR+ ) accord local standard &amp; HER2 positive : IHC 3+ , FISH ISH amplify ( locally assess ) &amp; Axillary lymph node status : 01 involve ( macro metastasis i.e . &gt; 2mm OR micro metastasis i.e . &gt; 0.22mm ) Previous diagnosis breast malignancy unless disease free 10 year Metastatic disease Tumor sample ship Agendia ≤ 30 % tumor cell fail QA QC criterion Women start complete adjuvant chemotherapy neoadjuvant chemotherapy current breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage I</keyword>
	<keyword>stage II</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>Triple Negative</keyword>
</DOC>